TCGA-A2-A25D-01A-12R-A16F-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.590
- INFLAMMATORY_RESPONSE+0.470
- OXIDATIVE_PHOSPHORYLATION+0.470
- MYC_TARGETS_V2+0.450
- TNFA_SIGNALING_VIA_NFKB+0.440
- IL6_JAK_STAT3_SIGNALING+0.420
- ADIPOGENESIS+0.390
- MYC_TARGETS_V1+0.380
Top 10 suppressed
- PROTEIN_SECRETION-0.400
- MITOTIC_SPINDLE-0.360
- NOTCH_SIGNALING-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- TGF_BETA_SIGNALING-0.290
- HEDGEHOG_SIGNALING-0.280
- UV_RESPONSE_DN-0.280
- G2M_CHECKPOINT-0.220
- APICAL_JUNCTION-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2785-01A-01R-0851-07 | — | cohortA1 | 0.888 |
| 2 | TCGA-BT-A42F-01A-11R-A23W-07 | — | — | 0.883 |
| 3 | 20100231.Her2HRpos | — | C | 0.882 |
| 4 | SRR8518165 | — | C | 0.877 |
| 5 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.832 |
| 6 | SRR8392897 | — | cohortSQ2 | 0.826 |
| 7 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.821 |
| 8 | TCGA-37-3783-01A-01R-1201-07 | — | cohortSQ1 | 0.818 |
| 9 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.809 |
| 10 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |